Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.

MLA

Naing, Aung, et al. “Exploring the Safety, Effect on the Tumor Microenvironment, and Efficacy of Itacitinib in Combination with Epacadostat or Parsaclisib in Advanced Solid Tumors: A Phase I Study.” Journal for Immunotherapy of Cancer, vol. 10, no. 3, Mar. 2022. EBSCOhost, https://doi.org/10.1136/jitc-2021-004223.

APA

Naing, A., Powderly, J. D., Nemunaitis, J. J., Luke, J. J., Mansfield, A. S., Messersmith, W. A., Sahebjam, S., LoRusso, P. M., Garrido-Laguna, I., Leopold, L., Geschwindt, R., Ding, K., Smith, M., & Berlin, J. D. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for Immunotherapy of Cancer, 10(3). https://doi.org/10.1136/jitc-2021-004223

Chicago

Naing, Aung, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, et al. 2022. “Exploring the Safety, Effect on the Tumor Microenvironment, and Efficacy of Itacitinib in Combination with Epacadostat or Parsaclisib in Advanced Solid Tumors: A Phase I Study.” Journal for Immunotherapy of Cancer 10 (3). doi:10.1136/jitc-2021-004223.